NCT02142777View on ClinicalTrials.gov

S-Equol in Alzheimer's Disease (SEAD) Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Alzheimer's Disease
Interventions
DRUG

S -Equol

We will determine if the intervention (S-equol) alters platelet mitochondria COX activity.

DRUG

Placebo

The placebo has no active ingredients but is made to look like the study drug.

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

Sponsors
All Listed Sponsors
collaborator

Ausio Pharmaceuticals, LLC

INDUSTRY

lead

Russell Swerdlow, MD

OTHER

NCT02142777 - S-Equol in Alzheimer's Disease (SEAD) Trial | Biotech Hunter | Biotech Hunter